VENITI Announces 1,000TH Patient Treated With VICI VENOUS STENT

FREMONT, Calif. and ST. LOUIS, June 20, 2016 /PRNewswire/ -- VENITI, Inc., the leader in the advancement of treatment for venous disease, announced today that physicians have treated over 1,000 patients with the VICI VENOUS STENT. The product received CE marking in October 2013 and was first implanted in January 2014. Subsequently, it has been launched in 13 countries worldwide. The unique stent design allows the physician to confidently treat the millions of patients suffering from chronic venous disease associated with venous outflow obstruction.

One of the busiest and advanced centers for deep venous therapy, Michael K. W. Lichtenberg, M.D., Chief of Angiology Clinic and Venous Center, Klinikum Arnsberg, Arnsberg DE, has performed more than 100 deep venous interventions in 2016.

"Despite the vigilance we have for the symptoms of chronic venous disease and venous outflow obstruction, I am continually amazed by the incidence of venous outflow obstruction and the impact it has on our patients. Having a stent designed for the venous anatomy, like the VICI VENOUS STENT, contributes to our ability to provide the care they need," said Dr. Lichtenberg. "What has been most satisfying is the rapid resolution of patients' symptoms and improvement in their quality of life. It is critical that all physicians be aware of the roles of reflux and obstruction in venous disorders."

Chronic venous disease comprises a number of venous disorders, ranging from varicose veins to venous ulcers. The most serious of these disorders are collectively known as chronic venous insufficiency, and affect more than 20 million adults across the United States and Western Europe¹. Venous disease is progressive and cyclical, marked by symptoms which include progressive leg pain and swelling, leg heaviness and skin changes. Physicians treat the obstructive component of chronic venous disease through minimally-invasive endovascular stenting procedures. VENITI is currently conducting the VIRTUS Trial to evaluate the safety and efficacy of the VICI VENOUS STENT for the treatment of chronic iliofemoral venous outflow obstruction under a U.S. Food and Drug Administration Investigational Device Exemption.

"We are thankful to Dr. Lichtenberg and other physicians who have supported VENITI and trusted the VICI VENOUS STENT to provide their patients with the highest standard of care for venous outflow obstruction," said Jeff Elkins, President and CEO of VENITI, Inc. "The challenges of the venous system are unique. The achievement of this milestone with the VICI VENOUS STENT is testimony to an excellent performance profile across a wide range of patients among varied practitioners in the real world. We are committed to further perfect our results through clinical and technical research."

About VENITI, Inc.
VENITI, Inc. is dedicated to advancing the treatment of venous disease through clinical research and innovative technology and solutions. VENITI partners with leading physicians in the development and training for therapies to care for the millions of patients suffering from venous disease. The VICI VENOUS STENT and VICI VERTO VENOUS STENT were developed specifically for the challenges of treating iliofemoral venous outflow obstruction. VENITI was founded in 2010 and is headquartered in St. Louis, MO, with technical operations in Fremont, CA. The VICI VENOUS STENT and VICI VERTO VENOUS STENT are CE marked under the European Medical Devices Directive (93/42/EEC) and commercially available in Europe. The VICI VENOUS STENT is approved by the Australian Therapeutic Goods Administration and commercially available in Australia. CAUTION: Investigational device. Limited by United States law to investigational use. The VICI VERTO VENOUS STENT is not approved for sale in the United States. VENITI and VICI VENOUS STENT are registered trademarks of VENITI, Inc. VICI VERTO VENOUS STENT is a trademark of VENITI, Inc. ©2016 VENITI, Inc. All Rights Reserved. Produced in the U.S. Learn more about VENITI and its products at www.veniti.com

Investor Contact:
Jeff Elkins
+1 (408) 464-2789
jelkins@veniti.com

Media Contact:
Rodney Marcy
+1 (303) 885-7546
rmarcy@veniti.com

MKT-102

Logo - http://photos.prnewswire.com/prnh/20160421/358440LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/veniti-announces-1000th-patient-treated-with-vici-venous-stent-300287173.html

SOURCE VENITI, Inc.